Business model

A business model built for the future

We are full life cycle investors creating value and offering support at any stage, from academic programs all the way to mature publicly traded companies.

What we need to create value

Experienced team

A collaborative team of doctors, academics, and drug developers coupled with seasoned venture capitalists, investment bankers, lawyers and operators with a strong compliance culture.

Scientific rigor

Our research process combines wide data-gathering with deep analysis to identify the most compelling assets, technologies, and modalities with the best chance of reaching patients.

Full lifecycle investing

Taking a long-term, full-lifecycle approach and having a true evergreen structure helps us avoid the structural constraints of venture-only or public-only vehicles.

Global reach

Great science takes place everywhere in the world. Our global reach helps us find and support innovation wherever it exists.

How we create value

Our purpose drives everything we do

Identify transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by our deep scientific understanding and a long-term approach to supporting innovative businesses, we invest in companies developing next-generation therapies and technologies that can significantly improve patients’ lives.

Identify unmet needs, Invest in relationships, Support through the life cycle

Our purpose

We power breakthrough therapies that transform the lives of millions

Broad Value Creation

Patient Benefits

11

RTW’s top 10 most successful investments since inception have commercialized 11 drugs

Portfolio Companies

34

Number of private investments that have had a liquidity event out of 61 total

Local Communities

12

Number of community organizations and research partners the RTW Foundation supported in responding to COVID needs in New York City

Ultrarare Disease

9

Rare disease research organizations supported through RTWF grants across six countries

RTW senior team

Roderick Wong, MD

Roderick Wong, MD

Managing Partner, Chief Investment Officer
Sabera Loughran

Sabera Loughran

Partner Emeritus, Founding COO and CFO
Naveen Yalamanchi, MD

Naveen Yalamanchi, MD

Partner, Portfolio Manager
Stephanie A. Sirota

Stephanie A. Sirota

Partner, Chief Business Officer
Peter Fong, PhD

Peter Fong, PhD

Partner, President
Gotham Makker, MD

Gotham Makker, MD

Partner, Head of Strategic Investments
Robert Aurigema

Robert Aurigema

Partner, Chief Operating Officer and Chief Financial Officer
Chris Seiter

Chris Seiter

Chief Corporate Finance Officer

This website is not intended to offer or to promote the offer or sale of the shares (the “Shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. persons” as defined in Regulation S (“US persons”) under the US Securities Act of 1933, as amended (the “Securities Act”). The materials contained herein are not for release, publication or distribution, directly or indirectly, in whole or in part, to any persons to whom or into or within any jurisdiction where to do so would constitute a violation of applicable law or regulation.

The information contained herein and on the pages that follow does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which, or to any person to whom, such an offer or solicitation would be unlawful.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the “Investment Company Act”), and as such holders of the Shares are not and will not be entitled to the benefits of the Investment Company Act. The Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, assigned or otherwise transferred, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not result in the Company being required to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. The offer and sale of the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan or South Africa. Potential users of the information contained herein and on the pages that follow are requested to inform themselves about and to observe all applicable restrictions.

The information contained herein and on the pages that follow may contain forward-looking statements. Any statement other than a statement of historical fact is a forward-looking statement. Actual results may differ materially from those expressed or implied by any forward-looking statement. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of its issuance. The Company may change these terms and conditions from time to time and any such changes will be posted on this website. Your access to this website is governed by the version of these terms and conditions then in force.

By clicking “Agree” below, you represent, warrant, undertake and agree that (1) you have read, understood and agree to be bound by the terms and conditions and other information set out herein, (2) you are permitted under applicable laws and regulations to receive the information contained herein and on the pages that follow, (3) you are either (a) located outside the United States and are not a US Person or (b) an existing shareholder of the Company who is a “qualified purchaser” as defined under the Investment Company Act and (4) you will not further transmit or send any information contained in this website to any other persons in the United States, to US Persons, or to any publications with a general circulation in the United States. If you cannot so represent, warrant, undertake and agree, you must click the button labelled “Decline” or otherwise exit this website.